Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by MrTAteamon Jun 17, 2020 4:50pm
119 Views
Post# 31162091

Questions not answered

Questions not answered
You 03:27 PM 
Dr.Copeland stated that Glenco was established 10 years ago; it is still prerevenue. How did you come up with the valuation?
You 03:32 PM 
Is Sunnybrook working with the protease inhibitors being developed by Amino Therapeutics?
 
You 03:41 PM 
The ELISA test has higher specificity than sensitivity. A screening test should have just the opposite as you would prefer false positives when screening. This ELISA fits more as a confirmatory test,not screening.
 
1. Why did Qsc spend $2 million buying 40% of Amino Therapeutics when they have yet to do any research towards Covid-19( your NR, Due to the recent pandemic Amino has just began the research based on prior published research;No clinical testing has yet been performed related to the potential Treatment) and only $1.5 million to Sunnybrook and Sinai that are actually doing research?
 
2. Any progress at Amino Therapeutics?

You 03:49 PM 
You have the capacity of 4-5 million tests /month. How much more can that be ramped up?
 

<< Previous
Bullboard Posts
Next >>